Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab

Published:2023 Issue: Volume:35 Page:
ISSN:1013-9087
Container-title:Annals of Dermatology
language:en
Short-container-title:Ann Dermatol

Author:

Han Ju Hee¹^ORCID,Yook Hwa Jung¹^ORCID,Bang Chul Hwan¹^ORCID,Lee Ji Hyun¹^ORCID,Park Young Min¹^ORCID,Lee Jun Young¹^ORCID

Affiliation:

1. Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Publisher

XMLink

Subject

Dermatology

Link

https://anndermatol.org/pdf/10.5021/ad.20.332

Reference5 articles.

1. Epidermolysis bullosa acquisita

2. Basement membrane antibodies in sera of haematopoietic cell recipients are associated with graft-versus-host disease

3. Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation

4. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease

5. Safety and efficacy of rituximab-based first line treatment of chronic GVHD

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP